Effect of topiramate augmentation in chronic schizophrenia: A placebo-controlled trial

Archives of Iranian Medicine

Volumn 14, Issue 4, 2011, Pages 270-275

  Behdani, Fatemeh ^a,b   Hebrani, Paria ^a,b   Rezaei Ardani, Amir ^a   Rafee, Esmaeel ^b  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chronic schizophrenia; Placebo controlled trial; Topiramate

Indexed keywords

CLOZAPINE; PLACEBO; TOPIRAMATE; ANTICONVULSIVE AGENT; DRUG DERIVATIVE; FRUCTOSE; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; ATAXIA; BLURRED VISION; CONSTIPATION; CONTROLLED STUDY; DIPLOPIA; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HAIR LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; NAUSEA; OUTCOME ASSESSMENT; PARESTHESIA; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SPEECH DISORDER; TREATMENT DURATION; TREMOR; WEIGHT REDUCTION; ADJUVANT CHEMOTHERAPY; CHRONIC DISEASE; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME;

ADULT; AGED; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CHRONIC DISEASE; CLOZAPINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84864407350     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Sadock BJ, Sadock VA. Comprehensive Textbook of Psychiatry. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2009.
2. Sadock BJ, Sadock VA. Kaplan & Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. 10th ed. Philadelphia: Lippincott Williams & Wilkins; 2007.
3. Deakin JFW, Slater P, Simpson MD, Gilchrist AC, Skan WJ, Royston AJ, et al. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem.1989; 52: 1781-1786.
4. Akhondzadeh S, Mackinejad K, Ahmadi-Abhari SA, Alem ZM. Does the addition of lamotrigine to risperidone improve psychotic symptoms and cognitive impairments in chronic schizophrenia? Therapy. 2005; 2: 399-406.
5. Williams HJ, Zamzow CR, Robertson H, Dursun SM. Effects of clozapine plus lamotrigine on phencyclidine-induced hyperactivity. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 30: 239-243.
6. Dursun SM, Deakin JF. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. J Psychopharmacol. 2001; 15: 297-301.
7. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: Support for hyperglutamatergic effects of N-methyl-daspartate receptor antagonists. Arch Gen Psychiatry. 2000; 57: 270-276.
8. Konradsson A, Marcus MM, Sitzia R, Svensson TH, Jardemark KE. Adjuvant treatment with the anticonvulsant drug topiramate in schizophrenia. European Neuropsychopharmacology. 2007; 17: S33-S34.
9. Deutsch SI, Rosse RB, Billingslea EN, Bellack AS, Mastropaolo J. Topiramate antagonizes MK-801 in an animal model of schizophrenia. Eur J Pharmacol. 2002; 449: 121-125.
10. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 1998; 281: 1349-1352.
11. Frau R, Orru M, Fa M, Casti A, Manunta M, Fais N, et al. Effects of topiramate on the prepulse inhibition of the acoustic startle in rats. Neuropsychopharmacology. 2007; 32: 320-331.
12. Deutsch SI, Schwartz BL, Rosse RB, Mastropaolo J, Marvel CL, Drapalski AL. Adjuvant topiramate administration: A pharmacologic strategy for addressing NMDA receptor hypofunction in schizophrenia. Clin Neuropharmacol. 2003; 26: 199-206.
13. Afshar H, Roohafza H, Mousavi G, Golchin S, Toghianifar N, Sadeghi M, et al. Topiramate add-on treatment in schizophrenia: A randomised, double-blind, placebo-controlled clinical trial. J Psychopharmacol. 2009; 23: 157-162.
14. Drapalski AL, Rosse RB, Peebles RR, Schwartz BL, Marvel CL, Deutsch SI. Topiramate improves decit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication. Clin Neuropharmacol. 2001; 24: 290-294.
15. Hosak L, Libiger J. Antiepileptic drugs in schizophrenia: a review. Eur Psychiatry. 2002; 17: 371-378.
16. Arnone D. Review of the use of topiramate for treatment of psychiatric disorders. Ann Gen Psychiatry. 2005; 4: 5.
17. Levine SZ, Rabinowitz J, Engel R, Etschel E, Leucht S. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophr Res. 2008; 98: 318-322.
18. Rabinowitz J, Mehnert A, Eerdekens M. To what extent do the PANSS and CGI-S overlap? J Clin Psychopharmacol. 2006; 26: 303-307.
19. Van den Oord EJ, Rujescu D, Robles JR, Giegling I, Birrell C, Bukszar J, et al. Factor structure and external validity of the PANSS revisited. Schizophr Res. 2006; 82: 213-223.
20. Johannessen LC. Antiepileptic drugs in non-epilepsy disorders: Relations between mechanisms of action and clinical efficacy. CNS Drugs. 2008; 22: 27-47.
21. Millson RC, Owen JA, Lorberg GW, Tackaberry L. Topiramate for refractory schizophrenia. Am J Psychiatry. 2002; 159: 675.
22. Eltayb A, Wadenberg ML, Schilstrom B, Svensson TH. Topiramate augments the antipsychotic-like effect and cortical dopamine output of raclopride. Naunyn Schmiedebergs Arch Pharmacol. 2005; 372: 195-202.
23. Tiihonen J, Halonen P, Wahlbeck K, Repo-Tiihonen E, Hyvarinen S, Eronen M, et al. Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry. 2005; 66: 1012-1015.
24. Migliardi G, Darrigo C, Santoro V, Bruno A, Cortese L, Campolo D, et al. Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders. Clin Neuropharmacol. 2007; 30: 107-113.
25. Ko YH, Joe SH, Jung IK, Kim SH. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol. 2005; 28: 169-175.
26. Welge JA, Keck PE Jr. Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression. Psychopharmacology (Berl). 2003; 166: 1-10.
27. Schneiderhan ME, Marvin R. Is acetazolamide similar to topiramate for reversal of antipsychotic-induced weight gain? Am J Ther. 2007; 14: 581-584.
28. Chengappa KN, Chalasani L, Brar JS, Parepally H, Houck P, Levine J. Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review. Clin Ther. 2002; 24: 1576-1584.
29. Huguelet P, Morand-Collomb S. Effect of topiramate augmentation on two patients suffering from schizophrenia or bipolar disorder with comorbid alcohol abuse. Pharmacol Res. 2005; 52: 392-394.
30. de Araujo Filho GM, Pascalicchio TF, Lin K, Sousa PS, Yacubian EM. Neuropsychiatric profiles of patients with juvenile myoclonic epilepsy treated with valproate or topiramate. Epilepsy Behav. 2006; 8: 606-609.
31. Duggal HS. Psychotic symptoms associated with topiramate: Cognitive side effects or worsening of psychosis? J Clin Psychiatry. 2004; 65: 1145-1146.
32. Hofer A, Fleischhacker WW, Hummer M. Worsening of psychosis after replacement of adjunctive valproate with topiramate in a schizophrenia patient. J Clin Psychiatry. 2003; 64: 1267-1268.
33. Kober D, Gabbard GO. Topiramate-Induced Psychosis. Am J Psychiatry. 2005; 162: 1542.
34. José RJ, Cairns A, Babbs C. Topiramate-induced psychosis in two members of the one family: a case report. J Med Case Reports. 2008; 2: 195.
35. Novick D, Bousono M, Suarez D, Olivares JM, Montejo AL, Haro JM, et al. SOHO Advisory Board. Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: Results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study. Prog Neuropsychopharmacol Biol Psychiatry. 2005; 29: 972-982.